Abivax S.A. ABVX 深 滬
已收盤 11-06 16:00:00 美东时间
85.73
+1.555
+1.85%
華盛通- 最 高86.82
- 今 開84.30
- 成交量 82.72万股
- 最 低 83.6305
- 昨 收 84.175
- 總市值 75.05亿
- 52周最高 148.83
- 市盈率 靜 --
- 換手率 0.94%
- 52周最低 69.81
- 委 比 14.21%
- 總股本 8754.15万
- 歷史最高 148.83
- 量 比 1.04
- 振 幅 3.79%
- 歷史最低 4.77
- 每 手 1
- 風險率 14.23%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 潜在涨幅203.03%！BTIG上调Rapport Therapeutics目标价至89美元，维持"买入"评级
今日重点评级关注：BTIG：维持Rapport Therapeutics"买入"评级，目标价从75美元升至89美元；摩根士丹利：维持希捷科技"超配"评级，目标价从1187美元升至1200美元
10-21 12:30
Guggenheim Reiterates Buy on Abivax, Maintains $175 Price Target
Guggenheim analyst Yatin Suneja reiterates Abivax (NASDAQ:ABVX) with a Buy and maintains $175 price target.
10-20 20:52
Abivax To Present Seven Scientific Abstracts On Obefazimod, Lead Drug Candidate For Treatment Of Active Ulcerative Colitis At UEG Week 2026 Meeting
Abivax to Present Data on Obefazimod at United European Gastroenterology (UEG) Week 2026 Four oral presentations and three posters build upon Phase 3 ABTECT Maintenance and Induction programs in ulcerative colitis, long-term Phase 2 findings, and preclinical anti-fibrotic research PARIS, France – Se...
10-01 04:16
美股牛股 | Kodiak暴升178%！wAMD三期临床试验大获成功；黑莓升逾7%，Q2营收超预期，QNX业务表现强劲
Kodiak暴升178%！wAMD三期临床试验大获成功；AMC升近12%，39.7亿美元债务再融资；黑莓升逾7%，Q2营收超预期，QNX业务表现强劲>>
09-29 17:03
美股周涨跌榜 | Grail暴升57%，首个多癌早筛PMA获专家组支持；Moderna飙升29%，市场关注黑色素瘤研究三期结果；Credo升近20%
Grail暴升57%，首个多癌早筛PMA获专家组支持；Moderna飙升29%，市场关注黑色素瘤研究三期结果；Credo升近20%，ECOC展示1.6T AI光互联新品>>
09-28 17:49
美股大行评级 | Muse热度发酵，Meta目标价获大幅升至875美元；闪迪获看好至2400美元，潜在升幅约27%
今日重点评级关注：Citizens：上调Quince Therapeutics评级至"跑赢大市"，目标价77美元；康托·菲茨杰拉德：维持塞德斯医疗"超配"评级，目标价从61美元升至72美元
09-23 15:30
Analysts’ Top Healthcare Picks: Abivax SA Sponsored ADR (ABVX), Biodesix (BDSX)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts jus...
09-22 21:50
These Analysts Slash Their Forecasts On Abivax Following H1 Results
Abivax SA (NASDAQ:ABVX) reported mixed results for the first half of the year on Monday. The company posted losses of $2.43 per share, compared to the analyst consensus estimate of losses of $1.08 per share. The company reported sales of $2.959 million which beat the analyst consensus estimate of $1...
09-22 21:28
Wedbush Maintains Neutral on Abivax, Lowers Price Target to $118
Wedbush analyst David Nierengarten maintains Abivax (NASDAQ:ABVX) with a Neutral and lowers the price target from $140 to $118.
09-22 20:40
Abivax H1 EPS $(2.43) Misses $(1.08) Estimate, Sales $2.959M Beat $1.860M Estimate
Abivax (NASDAQ:ABVX) reported quarterly losses of $(2.43) per share which missed the analyst consensus estimate of $(1.08) by 125 percent. This is a 65.31 percent decrease over losses of $(1.47) per share from the same period last year. The company reported quarterly sales of $2.959 million which be...
09-22 04:40
